Uses of the drug Parkxime

Parkxime's main ingredient is Fexofenadine, a second generation antihistamine. The drug has specific and selective antagonistic effects on H1 receptors in the digestive, respiratory and vascular systems. This article will provide information about the uses, dosage and precautions when using Parkxime.

Parkxime is a product of Aurochem Pharma Pvt., prepared in the form of film-coated tablets. Parkxime drug contains the active ingredient Fexofenadine, a second generation antihistamine with specific and selective antagonistic effects on H1 receptors. Fexofenadine is the active metabolite of terfenadine, which competes with histamine at H1 receptors in the digestive, vascular, and respiratory tracts. Parkxime is not cardiotoxic because it does not inhibit the potassium channel involved in myocardial repolarization. Fexofenadine has virtually no acetylcholine and dopamine antagonist effects and does not inhibit alpha 1 or beta-adrenergic receptors. At therapeutic doses, Parkxime does not induce sleep or affect the central nervous system. Parkxime drug is well absorbed when taken orally and begins to work 60 minutes after taking it. Antihistamine effects can last for more than 12 hours.

Parkxime is indicated for the symptomatic treatment of seasonal allergic rhinitis and chronic urticaria in adults and children over 6 years of age.
Parkxime is contraindicated in patients with hypersensitivity to Fexofenadine, Terfenadine or to any of the ingredients in the formulation.

3.1 Dosage of Parkxime
Adults:
Treatment of allergic rhinitis: The recommended dose is 60mg x 2 times/day or 180mg, taken once/day. Treatment of chronic idiopathic urticaria: The recommended dose is 60 mg twice a day or 180 mg orally once a day. Children:
Treatment of allergic rhinitis:
Children > 12 years old, use a dose of 60 mg x 2 times / day or 180 mg, orally 1 time / day. Children 2 to 11 years of age should receive a dose of 30 mg x 2 times / day. Chronic idiopathic urticaria:
Children 12 years of age and older: The recommended dose is 60mg x 2 times/day or 180mg, taken once/day. Children 2 to 11 years of age: 30mg twice daily is recommended. Children 6 months to 2 years of age: 15mg once daily is recommended. Children 2 to 11 years of age with renal impairment: The recommended dose is 30mg once daily. Other subjects:
Adults with renal impairment and the elderly: A dose of 60 mg orally once a day should be started and adjusted according to the patient's renal function. Specifically as follows: Glomerular filtration rate > 50mL/min: No dosage adjustment is required when administered twice daily (ie 60 mg every 12 hours). Glomerular filtration rate 10 to 50 mL/min: Use every 12 to 24 hours. Glomerular filtration rate <10 mL/min: Use every 24 hours. Intermittent hemodialysis or peritoneal dialysis: Use every 24 hours. Continuous renal replacement therapy (CRRT): A dose of 60 mg every 24 hours is recommended. 3.2. How to take Parkxime Drug Parkxime is taken orally. The time of taking the drug does not depend on the meal.

Patients using Parkxime may experience side effects including:
Frequency > 10%:
Central nervous system: Headache; Digestion: Vomiting. Frequency 1 to 10%:
Central nervous system: Drowsiness, fatigue, dizziness, pain, sleep disturbance; Gastrointestinal: Diarrhea, nausea, vomiting, dyspepsia; Genitourinary system: Dysmenorrhea; Infection: Risk of viral infection, upper respiratory tract infection, gonorrhea; Neuromusculoskeletal: Muscle pain, back pain, limb pain; Other: Otitis media, cough, fever, hypersensitivity reactions (including anaphylaxis, angioedema, chest tightness, dyspnea, flushing, pruritus, skin rash, urticaria), insomnia, anxiety, nightmares .

Care should be taken and appropriate dose adjustment is required when administering Parkxime to patients with impaired renal function because of increased plasma concentrations. Care should be taken when administering Parkxime to the elderly because patients often have physiological decline in renal function. The safety and effectiveness of Parkxime in children under 6 months of age have not been established. Parkxime should be discontinued at least 24-48 hours before conducting intradermal antigen tests. When used in combination with Pseudoephedrine, cautions and contraindications regarding Pseudoephedrine should be considered. A fixed combination preparation containing 180 mg of Fexofenadine hydrochloride and 240 mg of Pseudoephedrine hydrochloride should be avoided in patients with renal impairment due to the risk of accumulation of Pseudoephedrine. Risk of overdose and toxicity in children under 2 years of age when taking over-the-counter preparations containing antihistamines, expectorants, cough suppressants, and decongestants to relieve symptoms of upper respiratory tract infections. Therefore, the use of these products in pediatric patients < 2 years of age is not recommended and caution is recommended in pediatric patients ≥ 2 years of age. Overdose: There is limited information on the toxicity of fexofenadine overdose. Overdose symptoms may include drowsiness, dizziness, and dry mouth. To handle an overdose of Parkxime, the usual measures should be used to remove the unabsorbed portion of the drug from the gastrointestinal tract (inducing vomiting and gastric lavage), supportive treatment and symptomatic treatment for the disease. core. Hemodialysis does not significantly reduce the concentration of Parkxime in the blood. Pregnancy: There are currently no adequate data on the use of Parkxime in pregnant women. Therefore, the drug should only be used in pregnant women when the benefits outweigh the risks. Lactation: Fexofenadine may be distributed into breast milk. Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines. If a breastfed infant is exposed to second-generation antihistamines through breast milk, the infant must be carefully monitored for irritability, restlessness, or drowsiness.

Drug interactions that may alter the effectiveness of treatment and/or increase side effects. It is best for patients to inform their doctor of all medications, including prescription and non-prescription drugs and dietary supplements, for advice. The following are some interactions to be aware of when using Parkxime:
Erythromycin and Ketoconazole can increase the plasma concentration of Fexofenadine but do not change the QT interval. Fexofenadine should not be used concurrently with aluminum- and magnesium-containing antacids because it may reduce the absorption of Fexofenadine. Fexofenadine may increase the concentration of alcohol, sedatives and anticholinergics. Fexofenadine may decrease the concentration of Acetylcholinesterase and Betahistine inhibitors. Grapefruit juice can increase the concentration of Fexofenadine. Rifampin may decrease the serum concentration of Fexofenadine. Above is the general information about the drug Parkxime. The information above is for reference only and cannot replace the guidance of medical personnel. Patients should not use it on their own, but need to consult a medical staff.